Rheumatology

Featured Article

Rheumatoid Arthritis: Risk Factors, Diagnosis, and Treatment

Rheumatoid Arthritis: Risk Factors, Diagnosis, and Treatment

This article discusses the most prevalent risk factors, as well as the clinical signs and symptoms, associated with RA.

Latest

Second Biologic Effective in RA After Initial Treatment Failure

Second Biologic Effective in RA After Initial Treatment Failure

DMARDs alone or with methotrexate and tofacitinib plus methotrexate improved disease activity and remission rates in patients with RA who have not responded to previous biologic therapy.

Rheumatoid Arthritis Patients More Affected by Staphylococcus aureus Infections

Rheumatoid Arthritis Patients More Affected by Staphylococcus aureus Infections

Patients with RA suffering from S. aureus infection have more complications and higher mortality rates than patients without RA.

DMARDs Rheumatoid Arthritis Treatment Guidelines Updated

DMARDs Rheumatoid Arthritis Treatment Guidelines Updated

EULAR recommendations were updated for rheumatoid arthritis management to include new guidelines on starting effective therapy in patients early.

Glucocorticoids for Early Rheumatoid Arthritis: Assessing Long-term Safety

Glucocorticoids for Early Rheumatoid Arthritis: Assessing Long-term Safety

Patients with early RA treated with very low-dose glucocorticoids over 7 years experienced similar toxicity as patients who were not treated with glucocorticoids.

Alterations in Soluble Mediators May Predict Transition to Lupus

Alterations in Soluble Mediators May Predict Transition to Lupus

Preclinical alterations in levels of soluble mediators may predict transition to SLE for unaffected relatives of patients with SLE.

Secukinumab Improves Symptoms in TNFi-Refractory Rheumatoid Arthritis

Secukinumab Improves Symptoms in TNFi-Refractory Rheumatoid Arthritis

A phase 3, double-blind, randomized placebo-controlled study was conducted in 551 patients with active RA who received secukinumab, abatacept, or placebo.

Rheumatoid Arthritis Treatment: Baricitinib Superior to Adalimumab

Rheumatoid Arthritis Treatment: Baricitinib Superior to Adalimumab

This study included phase 3 trial in patients taking baricitinib, adalimumab, or placebo in addition to methotrexate background therapy.

Lupus: Improving Symptoms and Outcomes With Diet and Nutrition

Lupus: Improving Symptoms and Outcomes With Diet and Nutrition

Consuming adequate amounts of the right nutrients can help relieve symptoms and improve outcomes in patients with systemic lupus erythematosus.

Tocilizumab and Cardiovascular Risk in RA Patients

Tocilizumab and Cardiovascular Risk in RA Patients

No evidence was found of a higher cardiovascular risk among rheumatoid arthritis patients who switched from a different biologic drug or tofacitinib to tocilizumab vs to a tumor necrosis factor inhibitor.

Tofacitinib Compared With Adalimumab in RA Study

Tofacitinib Compared With Adalimumab in RA Study

Pfizer has announced top-line results from its Phase 3B/4 study comparing treatment with Xeljanz to adalimumab in patients with moderate to severe rheumatoid arthritis.